Gecko Biomedical Receives 1.4 Million Euros in Interest-Free Loan from Bpifrance to Advance Its Bio-Inspired Surgical Adhesiv...
June 30 2016 - 2:30AM
Business Wire
Gecko Biomedical (“Gecko”), a French medical device company
developing innovative polymers to support tissue healing, announces
today that it has received an interest-free loan of 1.4 million
euros from Bpifrance to advance its bio-inspired surgical adhesive
solutions.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160629005998/en/
Gecko Biomedical Polymer (photo by
Patrick Parchet)
These funds will be dedicated to supporting Gecko Biomedical
clinical trials in Europe in order to obtain CE Mark in the first
half of 2017.
The funds are part of Bpifrance’s support of innovation through
its interest-free loan program (Prêt à Taux Zéro pour l’Innovation
-PTZI), providing repayable advances to encourage the development
of innovative products.
Christophe Bancel, Gecko Biomedical’s Chief Executive Officer,
said “Bpifrance’s continuous support not only provides us with
financial stability towards our future, but also is a testimony of
the value of our biopolymers platform. As such, Bpifrance is a
central stakeholder to our short, medium and long-term
development.”
###
About GeckoGecko Biomedical is a privately owned medical
device company based in Paris, France that is dedicated to the
rapid development and commercialization of a unique biopolymers
platform. Gecko’s first product (GB-02) is an innovative polymer
for tissue healing, targeting cardiovascular reconstruction as an
initial indication. The structure of GB-02 is tunable, allowing
customization for various applications and tissues. Gecko’s
biopolymers platform is fully industrialized and highly versatile,
with potential novel applications in other fields of tissue
reconstruction, such as guided tissue repair and localized drug
delivery.Gecko’s platform is based on proprietary biopolymers with
unique chemical and physical properties, including high viscosity,
hydrophobicity and fast “on demand” curing for precise local
delivery and in situ adhesion. The Company’s technologies are
derived from world-class research and intellectual property from
the laboratories of Pr Robert Langer (MIT) and Pr Jeff Karp
(Brigham and Women’s Hospital), who co-founded the company in 2013,
alongside Christophe Bancel and Bernard Gilly from the iBionext
Network.For more information, please visit www.geckobiomedical.com
and follow @geckobiomedical
About BpifranceBpifrance, a subsidiary of Caisse des
Dépôts and the French State, is a trusted partner of entrepreneurs
which provides companies with credit, collateral and equity
financing support from start up through to stock exchange listing.
Bpifrance also provides guidance services and enhanced support for
innovation, external growth and export, in partnership with
Business France and Coface.Bpifrance offers companies a continuum
of financing for each key stage of their development and an offer
adapted to specific regional features. With 42 regional offices
(90% of decisions are made regionally), Bpifrance offers
entrepreneurs a tool for economic competitiveness. Bpifrance works
in support of the public policies pursued nationally and regionally
by the French government, to meet three objectives:
- support the growth of businesses;
- prepare for future
competitiveness;
- contribute to the development of a
favorable ecosystem for entrepreneurship.
With Bpifrance, companies have a strong and effective local
contact to meet all their financial, innovation and investment
needs.For more information, please visit: www.bpifrance.fr –
http://investissementsdavenir.bpifrance.fr/ – Twitter:
@bpifrance
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160629005998/en/
PRESS CONTACTSFor GeckoChristophe BANCEL, Tel: +33 1 76
21 72 28cbancel@geckobiomedical.comTwitter:
@geckobiomedicalorFor BpifranceNathalie POLICE, Tél: +33 1
41 79 95 26nathalie.police@bpifrance.frTwitter: @bpifrance